Fenniche Salma, Oukabli Mohamed, Oubaddou Yassire, Chahdi Hafsa, Damiri Amal, Alghuzlan Abir, Laraqui Abdelilah, Dakka Nadia, Bakri Youssef, Dupuy Corinne, Ameziane El Hassani Rabii
Laboratory of Biology of Human Pathologies (BioPatH), Faculty of Sciences, Mohammed V University in Rabat, Rabat 1014, Morocco.
Gustave Roussy Cancer Campus, Pavillon de Recherche N°2, F-94805 Villejuif, France.
Curr Issues Mol Biol. 2023 Jul 13;45(7):5811-5823. doi: 10.3390/cimb45070367.
The comparative analysis of the expression of the reactive oxygen species-generating NADPH oxidase NOX4 from TCGA data shows that the NOX4 transcript is upregulated in papillary thyroid carcinomas (PTC)-BRAF tumors compared to PTC-BRAF tumors. However, a comparative analysis of NOX4 at the protein level in malignant and non-malignant tumors is missing. We explored NOX4 protein expression by immunohistochemistry staining in malignant tumors (28 classical forms of PTC (C-PTC), 17 follicular variants of PTC (F-PTC), and three anaplastic thyroid carcinomas (ATCs)) and in non-malignant tumors (six lymphocytic thyroiditis, four Graves' disease, ten goiters, and 20 hyperplasias). We detected the BRAF mutation by Sanger sequencing and digital droplet PCR. The results show that NOX4 was found to be higher (score ≥ 2) in C-PTC (92.9%) compared to F-PTC (52.9%) and ATC (33.3%) concerning malignant tumors. Interestingly, all C-PTC-BRAF expressed a high score for NOX4 at the protein level, strengthening the positive correlation between the BRAF mutation and NOX4 expression. In addition, independent of the mutational status of BRAF, we observed that 90% of C-PTC infiltrating tumors showed high NOX4 expression, suggesting that NOX4 may be considered a complementary biomarker in PTC aggressiveness. Interestingly, NOX4 was highly expressed in non-malignant thyroid diseases with different subcellular localizations.
通过对TCGA数据中活性氧生成NADPH氧化酶NOX4表达的比较分析表明,与PTC - BRAF肿瘤相比,NOX4转录本在甲状腺乳头状癌(PTC)- BRAF肿瘤中上调。然而,目前尚缺乏对恶性和非恶性肿瘤中NOX4蛋白水平的比较分析。我们通过免疫组织化学染色在恶性肿瘤(28例经典型PTC(C - PTC)、17例PTC滤泡变体(F - PTC)和3例间变性甲状腺癌(ATC))和非恶性肿瘤(6例淋巴细胞性甲状腺炎、4例格雷夫斯病、10例甲状腺肿和20例增生)中探究NOX4蛋白表达。我们通过桑格测序和数字液滴PCR检测BRAF突变。结果显示,在恶性肿瘤中,C - PTC(92.9%)中NOX4水平高于F - PTC(52.9%)和ATC(33.3%)(评分≥2)。有趣的是,所有C - PTC - BRAF在蛋白水平上NOX4均表达高分,强化了BRAF突变与NOX4表达之间的正相关。此外,独立于BRAF的突变状态,我们观察到90%的C - PTC浸润性肿瘤显示高NOX4表达,表明NOX4可被视为PTC侵袭性的一种补充生物标志物。有趣的是,NOX4在具有不同亚细胞定位的非恶性甲状腺疾病中高表达。